All In Biotech

Drug Trial Radar · NCT07497594

ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

Expanding PrEP Options Among Young MSM, Transgender and Non-binary Persons in Brazil: Incorporating Twice-yearly Lenacapavir for HIV Prevention - The ImPrEP LEN Brasil Study

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

Feb 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Oswaldo Cruz FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP). The main questions it aims to answer are: How many participants get HIV while using long-acting lenacapavir? How safe is long-acting lenacapavir in real-world health services? How many participants continue using their chosen prevention method over time? What factors help or make it harder for participants to stay on prevention? Researchers will compare two HIV prevention options to understand how they work in routine care: Long-acting lenacapavir, given as an injection under the skin every 6 months, Daily oral pre-exposure prophylaxis (PrEP), taken as a pill containing tenofovir disoproxil fumarate and emtricitabine, Participants will choose the prevention option they prefer after receiving counseling. This is not a randomized study. Researchers will follow participants for up to 2 years. Participants will: Receive either an injection every 6 months or take a daily pill, Visit the clinic regularly for HIV testing and health checkups, Receive testing and treatment for sexually transmitted infections, Answer questions about their health, medication use, and experiences, Receive prevention counseling and condoms. This study will help health services understand how to offer long-acting HIV prevention in Brazil and how to better support people who want to prevent HIV infection.

Conditions

  • Contact With or Exposure to Human Immunodeficiency Virus

Interventions

  • Lenacapavir long-actingDrug

    Approximately 1200 participants who choose long acting Lenacapavir will receive an oral loading dose consisting of 600 milligrams on Day 1 and 600 milligrams on Day 2, followed by 300 milligrams on Day 8, according to the clinical protocol, followed by subcutaneous administration of Lenacapavir at a dose of 927 milligrams per injection, administered at the enrollment visit and repeated every six months, totaling up to four administrations during the follow up period, combined with regular clinical visits for safety assessment, human immunodeficiency virus testing, monitoring of adverse events and serious adverse events, evaluation of injection site reactions, combined prevention counseling, screening and management of sexually transmitted infections, hepatitis B and hepatitis C, and monitoring of adherence to the injection schedule

  • Tenofovi-Emtricitabine (TDF/FTC) tabletDrug

    Approximately 300 participants who choose oral human immunodeficiency virus pre exposure prophylaxis will receive oral tenofovir disoproxil fumarate 300 milligrams combined with emtricitabine 200 milligrams in a fixed dose combination administered once daily on a continuous basis, with regular medication dispensing, periodic clinical follow up, serial human immunodeficiency virus testing, monitoring of adverse events, assessment of self reported adherence, combined prevention counseling, and screening and management of sexually transmitted infections and viral hepatitis, for up to 24 months of follow up

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who remain persistent on Lenacapavir pre-exposure prophylaxis at 24 monthsTime frame: From enrollment to 24 months of follow-up
  2. Time to discontinuation of Lenacapavir pre-exposure prophylaxisTime frame: Up to 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Fundação de Medicina Tropical Heitor Vieira Dourado

    Manaus, Amazonas, Brazil · Recruiting

  • CEDAP - Centro Especializado em Diagnóstico, Assistência e Pesquisa

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Hospital Geral de Nova Iguaçu

    Nova Iguaçu, Rio de Janeiro, Brazil · Recruiting

  • Instituto Nacional de Infectologia Evandro Chagas

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • CTA/Policlínica Centro

    Florianópolis, Santa Catarina, Brazil · Recruiting

  • Centro de Referência em IST/Aids de Campinas (SMS/PMC)

    Campinas, São Paulo, Brazil · Recruiting

  • Coordenadoria de IST/Aids da Cidade de São Paulo

    São Paulo, São Paulo, Brazil · Recruiting

  • Centro de Referência e Treinamento em DST/Aids de São Paulo

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.